High-dose recombinant erythropoietin treatment after experimental SAH in rats: pharmacokinetics and clinical assessment

E. Güresir, A. Raabe, N. Vasiliadis, S. Dias, V. Seifert & H. Vatter
Objective: Recombinant Erythropoietin (rEPO) is neuroprotective in animal models of hypoxic ischemia and traumatic brain injury. Our objective was to determine the pharmacokinetics and neurological improvement after administration of rEPO in the double-SAH model of the rat simulating delayed cerebral[for full text, please go to the a.m. URL]